# Clear cell RCC is the most common form of kidney cancer, accounting for roughly 75–80% of cases.

*biotech · news · 2026-04-21 · Benzinga*

## Key points

- The Keytruda-Lenvima-Welireg triplet regimen failed to meet PFS and OS endpoints in trial.
- MK-1308A plus Lenvima also did not outperform Keytruda plus Lenvima in the interim analysis.
- Safety profiles for the new regimens matched those seen in previous studies, with no new concerns.
- Analysts suggest these results may open opportunities for zanzalintinib-based HIF-2 alpha regimens in RCC.

**Companies:** Merck, Eisai
**Countries:** United States

[Read the full story on Benzinga](https://www.benzinga.com/markets/biotech/26/04/51949696/why-is-merck-stock-falling-tuesday)

---

Canonical: https://newsio.io/n/bf4a6dac-218d-4965-9439-d847c91f8f74/clear-cell-rcc-is-the-most-common-form-of-kidney-cancer-accounting-for-roughly-7
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works